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ABSTRACT 
 Colon and breast cancers are amongst the leading causes of cancer deaths in the 
United States, mostly attributed to metastasis and resistance to therapy.  Hence, there is a 
critical need to identify novel biomarkers for effective prognosis and to design targeted 
therapies to combat the metastatic diseases.  Loss of heterozygosity (LOH) at 
chromosome 18q and inactivation of the target gene, SMAD4, corresponds to resistance 
to the common chemotherapeutic agent, 5-fluorouracil (5-FU), in colon cancer.  Our 
examination of the therapeutic resistance phenomenon in SMAD4-negative colon cancer 
cells with the three common agents revealed significant resistance to both 5-FU and 
irinotecan but not to oxaliplatin.  We also followed up with the earlier findings from our 
group, which suggested that SMAD4 might interact with metastasis-promoting factors to 
suppress metastatic progression and render sensitivity to chemotherapy.  Co-
immunoprecipitation and mass spectrometry analysis revealed that SMAD4 interacts with 
and inhibits RICTOR, a component of mTORC2 that activates oncogenic AKT via 
	
	 viii 
phosphorylation at Serine 473.  Overexpression of SMAD4, depletion of RICTOR, or 
inhibition of AKT signaling restores sensitivity to irinotecan in SMAD4-negative colon 
cancer cells in vitro.  Furthermore, as expected pharmacological inhibition of AKT 
sensitizes these cells to irinotecan in vivo.  Interestingly, high RICTOR/AKT expression 
correlates with worse survival in colon cancer patients, suggesting them as novel 
prognostic biomarkers and therapeutic targets.  On the other hand, triple-negative breast 
cancer (TNBC) is the most aggressive form of breast cancer due to lack of effective 
targeted therapies.  Using miRNA expression profiling of a model for epithelial-
mesenchymal transition in TNBC, we found suppression of miR-4417 during the 
progression from non-malignant to malignant stage.  Furthermore, localization of miR-
4417 to chromosome 1p36, a region corresponding to high frequency of LOH in multiple 
cancers and low-level expression in TNBC patients associated with poor overall survival 
is consistent with its likely role as a tumor suppressor.  Interestingly, we found that 
overexpression of miR-4417 is sufficient to inhibit migration and tumorigenecity of 
TNBC cells in vitro.  Overall, our findings suggest miR-4417 exerts a tumor-suppressive 
effect and could serve as a novel prognostic biomarker and therapeutic tool against 
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Colon cancer incidence has declined steadily over the years due to preventive 
strategies, where premalignant lesions are removed upon detection using colonoscopy 
before progression of the diseases to the more malignant stage.  Nevertheless, it remains 
as the second leading cause of cancer deaths in men and women combined in the United 
States, where patients succumb to the disease due to metastatic progression and resistance 
to therapy (1).  While prevention is highly effective, there is still a critical, medical need 
to develop therapies to treat diseases that have progressed and subsequently developed 
resistance to standard treatments.  The three common chemotherapeutics, 5-fluoruracil 
(5-FU), irinotecan, and oxaliplatin, are widely used as first-line therapy against local and 
metastatic colon cancers (2).  Mechanistically, the three drugs prevent DNA synthesis or 
replication: 5-FU targets thymidylate synthases while irinotecan inhibits DNA 
topoisomerase 1, with oxaliplatin crosslinking the DNA.  The drugs are used in different 
combinations, FOLFIRI (5-FU+irinotecan), FOLFOX (5-FU+oxaliplatin), FOLFOXIRI 
(5-FU+oxaliplatin+irinotecan).  However, there are no biomarkers to guide the 
chemotherapy regimens, as they are only removed when toxicity occurs (2).  Therefore, it 
would be useful to identify biomarkers that could help predict response to these 
chemotherapeutics and devise strategies to circumvent resistance and suppress disease 
progression. 
 
On the other hand, breast cancers is the most frequently diagnosed and second 




metastasis and resistance to therapy (1).  Clinically, breast cancer is classified based on 
the expression of three biomarkers on the biopsied tissue: estrogen receptor (ER) 
progesterone receptor (PR), and HER2.  The most common subtype is the ER and PR-
positive, collectively known as hormone receptor-positive (HR-positive), which accounts 
for around 65% of all cases.  This is followed by the HER2-postive subtype, which 
constitutes 20% of all breast cancer diagnosis, and triple-negative (ER, PR, and HER2-
negative), which accounts for 15% (3-5).  Targeted therapies such as tamoxifen and 
aromatase inhibitors (which suppress HR signaling) and Herceptin (which suppresses 
HER2 signaling) have been developed against HR-positive and HER2-subtypes; 
however, there are no effective targeted therapies again triple-negative breast cancer 
(TNBC), resulting in poor survival in this patient subpopulation.  Moreover, TNBC is 
usually higher grade with poorly differentiated tissues upon diagnosis (5).  Hence, it 
would be medically beneficial to identify novel biomarkers that could serve as 
therapeutic tools to suppress progression of TNBC.   
  
The dissertation is divided into two chapters, each exploring the molecular 
underpinnings of tumor suppression in colon and triple-negative breast cancers, with the 
common goals to identify biomarkers that could inform prognosis, guide treatments, and 
enhance survival.  









Despite preventive screening, colon cancer remains as the second most lethal 
cancer in men and women combined in the United States with more than 50,000 deaths 
estimated to occur in 2018, mostly attributed to metastasis and resistance to therapy (1).  
The majority of colon cancer cases are of sporadic origin and surgery has limited 
therapeutic role in cases with metastatic colon cancer as only 10-15% of patients have 
resectable lesions (6).  Multiple first- and second-line chemotherapeutic options are 
available to combat metastatic disease, including 5-fluorouracil (5-FU), oxaliplatin (L-
OHP), and irinotecan (CPT-11).  For metastatic colon cancer, 5-FU in combination with 
irinotecan has been proven to be more effective than 5-FU alone in improving patient 
survival (7).  Intriguingly, screening of biomarkers to predict response to these agents is 
not implemented and an agent is only removed during subsequent regimens when 
intolerable toxicity occurs (2).  Due to toxicities caused by chemotherapeutic agents, it 
would be more effective to combine single agents with therapies directed at biological 
targets.  Therefore, understanding the molecular basis of metastatic colon cancer will be 





Loss of heterozygosity (LOH) at chromosome 18q has long been established as a 
late event during colon cancer progression (8, 9).  Furthermore, several studies have 
suggested that LOH at 18q was an indicator of a poor prognosis in patients with tumors 
penetrating the bowel wall or involving regional lymph nodes (TNM stages II and III, 
respectively) who succumbed to disease recurrence and died within 5 years of surgical 
removal of their primary tumor (10, 11).  In an attempt to identify the target gene(s) for 
18q deletions in colon cancer, we found SMAD4 mutations or genomic deletions of this 
gene (12).  This has been confirmed in numerous follow up studies that a high frequency 
of LOH at 18q was associated with an increase in the frequency of SMAD4 mutations, 
which occur in 10-30% of colon cancer and correlated to an advanced stage colon cancer 
(13-15).  Furthermore, when tumors corresponding to different stages of colon cancer 
were interrogated for SMAD4 inactivation arising from deletions or point mutations, there 
was a strong correlation between increasing frequency of SMAD4 gene mutations and 
distant metastases (stage IV) relative to non-metastatic colon cancer (16, 17).  A strong 
correlation between loss of SMAD4 expression and liver metastasis with poor prognosis 
in colon cancers (the most common site for colon cancer metastases) has also been 
established from the examination of primary tumors and the corresponding metastatic 
tissues (17-19).  In addition to colon cancer, a tumor suppressive role corresponding to 
mutations, deletions and low levels of SMAD4 has been associated with poor prognosis 





Moreover, credence to the contribution of SMAD4 defect in forming metastatic 
colon cancer was also derived from mouse models where a dramatic increase in 
malignant progression of intestinal polyps in cis-compound heterozygotes (i.e., Apc (+/-) 
Smad4 (+/-) compared to the simple Apc (+/-) heterozygotes was observed (25). 
Subsequently, inactivation of SMAD4 in human intestinal organoid models was crucial in 
showing tumor progression to the malignant and invasive stages of colon cancer (26).  In 
vitro and xenotransplantation studies further supported the tumor suppressive function of 
SMAD4, whereupon removal it promotes malignant phenotypes including cell migration, 
tumorigenesis, angiogenesis, aerobic glycolysis, and metastasis (27, 28).  Clinically, loss 
of or low SMAD4 expression correlated with presence of metastasis and has been 
associated with poor response to 5-FU and worse survival post-5-FU treatment (29, 30).  
While studies have shown that SMAD4-negative colon cancer is more resistant to 5-FU, 
whether and how SMAD4 inactivation confers resistance to other standard 
chemotherapeutics, such as oxaliplatin and irinotecan, remains to be discerned. 
 
Here, we report that among the three commonly used chemotherapeutic agents to 
treat colon cancer, SMAD4-negative colon cancer cells exhibit resistance to both 5-FU 
and irinotecan but not to oxaliplatin.  Furthermore, we found that inactivation of SMAD4 
leads to overactivation of the mTORC2 pathway, thereby augmenting AKT signaling and 
resistance to irinotecan-mediated apoptosis.  Consistent with these observations, targeting 
AKT with SMAD4 overexpression, RICTOR depletion, or MK2206, an AKT inhibitor, 




Materials and Methods 
 
Cell culture 
HCT116 SMAD4+/+ and SMAD4-/- isogenic cell lines are a generous gift from Dr Bert 
Vogelstein, while SW403, ASPC1, and CFPAC1 cells were obtained from ATCC.  
HCT116 and SW403 cells were cultured in McCoy’s medium.  ASPC1 cells were 
maintained in RPMI medium, while CFPAC1 cells were cultured in IMDM.  All cell 
lines were maintained in the presence of 10% FBS and 1% penicillin/streptomycin in a 
37°C incubator with 5% CO2.  
 
Co-immunoprecipitation 
Cells were washed with PBS and incubated with 1mM dithiobis succinimidyl propionate 
(DSP) at room temperature for 30 minutes.  The crosslinking reaction was quenched 
using 10mM Tris for 15 minutes.  Cells were then washed and lysed with Pierce IP buffer 
in the presence of protease and phosphatase inhibitors (Roche).  Protein lysates were 
scraped from the dish using cell lifters and centrifuged for 15 minutes at 14,000g at 4°C.  
Anti-FLAG affinity gel (Sigma-Aldrich) was washed three times with Pierce IP buffer 
and mixed with cell lysate overnight at 4°C.  The beads were then washed 3 times with 
Pierce IP buffer to remove unbound proteins.  The beads were incubated with 3xFLAG 






Mass spectrometry analysis 
Eluate from co-immunoprecipitation was mixed with 4xLDS buffer and 10x reducing 
agent before being loaded onto NuPAGE 4-12% pre-cast gels and separated for 15 
minutes at 100V.  The gel area with trapped eluate was then excised and digested with 
trypsin.  The digested samples were then analyzed with LC/MS/MS and subjected to 
Mascot database search for protein identification.  Protein candidates detected as 
background in more than 10 experiments among the total 411 experiments curated by the 
CRAPome database were first filtered (31).  Next, protein candidates that were enriched 
more than 5-fold based on spectral counts in the sample compared to control were then 
uploaded to Ingenuity Pathway Analysis for direct protein-protein interaction analysis to 
determine if they form any protein complexes.    
 
Kaplan-Meier analysis 
A database of colon cancer patients was established as described previously (32).  
Survival curves were generated based on the transcript level of a candidate gene using the 
Cox proportional hazards regression analysis and plotting Kaplan-Meier plots as 
described (33).  A p-value below 0.05 was accepted as a significant correlation between 









Student’s t-test (two-tailed, type two) was used for all statistical analysis.  Error bars 
represent standard deviation.  A p-value below 0.05 was considered statistically 
significant.  All experiments were performed in triplicates.  
 
Plasmid construction and viral transduction 
SMAD4 was PCR-amplified from pBabe-SMAD4-puro vector (27) and inserted at Xho1 
and BamH1 sites by ligation into the pNTAP-WB1 vector (containing FLAG and HA-
tags and blasticidin resistance marker) obtained from Dr William C. Hahn (34).  The 
correct SMAD4 sequence was confirmed by DNA sequencing.  The resulting pN-SMAD4 
retroviral expression vector, along with pCL-ampho retroviral packaging vector, and 
Xtreme-Gene transfection agent, were mixed in OptiMEM and then added to HEK293FT 
cells for 48 hours.  Medium containing virus was then collected and run through 0.45µm 
filters.  The viral medium was added to target cells in the presence of 10µg/ml polybrene 
for 24 hours.  The cells were then fed with fresh media and selection of transduced cells 
was performed using 5µg/ml of blasticidin.   
 
Western blotting 
Cells were lysed with RIPA buffer in the presence of protease and phosphatase inhibitors.  
Protein lysates were then scraped from the dish using cell lifters and centrifuged for 15 
minutes at 14,000g at 4°C.  Protein supernatant was mixed with 4xLDS buffer and 10x 




2 hours at 100V.  Proteins were then transferred to a PVDF membrane overnight at 4°C.  
The membrane was blocked with 5% milk for 30 minutes at room temperature and then 
incubated with primary antibodies overnight at 4°C.  The membrane was washed with 
TBS-T for 5 minutes three times and incubated with secondary antibodies for 1 hour at 
room temperature.  Membranes were washed with TBS-T for 5 minutes three times and 
incubated with enhanced chemiluminescence agent.  Films were used for the 
visualization of protein bands of interest.  Antibodies used were as follows: SMAD4, 
phospho-SMAD2, RICTOR, mTOR, phospho-AKTS473, AKT, cleaved caspase 3 from 
Cell Signaling Technology; FLAG, ACTIN from Sigma-Aldrich. 
 
shRNA cloning and stable gene knockdown 
shRNA oligonucleotides were annealed and ligated to pLKO.1-blast lentiviral expression 
vector.  The correct shRNA sequence was confirmed by sequencing.  The pLKO.1 
vector, psPAX2 and pMD2.G packaging vectors, and Xtreme-Gene were then mixed in 
OptiMEM and added to to HEK293 cells for 48 hours.  Viral medium was run through 
0.45µm filters and added to target cells for 24 hours in the presence of 10µg/ml 
polybrene.  Cells were fed with fresh media and selection of transduced cells was 
performed using 5µg/ml of blasticidin.   
 
Table 1: Sequence of shRNA oligonucleotides ligated into pLKO.1-blast plasmid. 
shScrambled (shSCR): 





R: 5’ AATTCAAAAA CCTAAGGTTAAGTCGCCCTCG CTCGAG 
CGAGGGCGACTTAACCTTAGG 
shRICTOR: 
F: 5’ CCGG GCAGCCTTGAACTGTTTAA CTCGAG  
TTAAACAGTTCAAGGCTGC TTTTTG 
R: 5’ AATTCAAAAA GCAGCCTTGAACTGTTTAA CTCGAG 
TTAAACAGTTCAAGGCTGC 
 
Reverse Transcription-quantitative PCR (RT-qPCR) 
Total RNA was isolated from cells using Direct-zol RNA Miniprep kit.  RNA was 
converted to cDNA using Super Script III Reverse Transcriptase.  The cDNA samples 
were mixed with Power SYBR Green PCR Master Mix and qPCR primers, and then run 
on 7900HT Real-Time PCR system to quantify relative expression level of target genes.   
 
Table 2: Sequence of qPCR primers for target genes in colon cancer.  
RICTOR: 
 
F: 5’ TTTACACTGCTTGCCAACCC 
R: 5’ ACTGATCCCGTTTCTGGTGT 
β-ACTIN: 
 
F: 5’ CGAGCACAGAGCCTCGCCTTTGCC 






Transwell migration assay 
Cells were serum-starved overnight, trypsinized, and resuspended in serum-free media.  
The cells were then seeded on transwell permeable supports with 8µm pores on a 24-well 
plate.  Cells were allowed to migrate towards serum-containing medium, which serves as 
a chemoattractant, for 24 hours. Migrated cells were then dissociated from the basal side 
of the transwell using Hank’s-based Cell Dissociation Buffer, stained with Calcein-AM, 
and quantified using a plate reader. 
 
Luciferase reporter assay 
SBE4-firefly luciferase reporter plasmid along with Renilla luciferase plasmid as an 
internal control were transfected into cells using Xtreme-Gene transfection agent for 72 
hours.  The cells were then lysed with Passive Lysis Buffer (Promega, Dual-Luciferase 
Reporter Assay) and luciferase activity was measured using GlowMax luminometer.  
Firefly/Renilla luciferase activity ratio was used to compare promoter activity between 
samples. 
 
Drug treatment and IC50 analysis 
Cells were seeded on a 96-well plate for 24 hours and treated with single or a 
combination of agents for 72 hours.  CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay (MTS, Promega) reagent was then added to the cells and relative 
absorbance at 490nm was measured using a plate reader.  The IC50 of a drug in target 




from Sigma-Aldrich; oxaliplatin, irinotecan, sirolimus, and MK2206 were purchased 
from SelleckChem.  Stock solutions in DMSO in 10mM were prepared and stored at -
20°C. 
 
Tumor xenograft studies 
The Institutional Animal Care and Use Committee at Boston University School of 
Medicine approved all animal experiments.  Six-week old female athymic nude mice 
(Nu/Nu) were purchased from Envigo and housed in a sterile environment with 
microisolator cages.  The mice were subcutaneously injected with 2.5 x 106 HCT116 
SMAD4-/- cells in 30% growth factor-reduced Matrigel (Corning).  When the tumors 
reached around 5mm in diameter, the mice were exposed to vehicle, MK2206 
(MedChemExpress) alone, irinotecan (MedChemExpress) alone, or a combination of 
MK2206 and irinotecan.  MK2206 (360mg/kg) in 30% Captisol was administered on 
days 1, 8, 15, and 22 via oral gavage.  Irinotecan (20mg/kg) was administered on days 1, 
8, 15, and 22 via intraperitoneal injections.  Tumor volume was determined using (L x 







SMAD4-negative colon cancer cells exhibit higher migratory ability and resistance 
to 5-fluorouracil and irinotecan  
 
To determine whether SMAD4 suppresses cancer progression in our colon cancer 
model, we first compared the migratory ability of a pair of isogenic SMAD4-positive and 
negative HCT116 cells.  While the SMAD4 gene was knocked out using targeted 
homologous integration, TGFβRII was restored to reconstitute intact TGFβ signaling in 
HCT116 cells as previously described (27, 35).  As expected, SMAD4-negative cells 
exhibited higher migratory potential than SMAD4-positive cells, which was in 
concurrence with previous reports that SMAD4 inactivation promoted malignant 






Figure 1: SMAD4 inactivation promotes migration in colon cancer cells. 
SMAD4+/+ and SMAD4-/- colon cancer cells were serum-starved and seeded on transwells and 
allowed to cross the membrane for 24 hours (transwell migration; RFU, relative fluorescence 
unit; mean + SD, n = 3; **P < 0.01).  
 
 To assess whether SMAD4 expression level could serve as a prognosis biomarker 
in colon cancer patients, we performed in silico Kaplan-Meier analyses and found that the 
probability of overall survival (OS), relapse-free survival (RFS), and post-progression 
survival (PPS) decreased significantly in patients with low levels of SMAD4 expression 
(Figure 2) (32, 33).  Overall, these findings provide additional credence in support of the 







Figure 2: Low expression of SMAD4 correlates with worse prognosis in colon 
cancer. 
In silico Kaplan-Meier analyses showing the correlation between SMAD4 (probe 235735_at) 
expression and A) overall survival (OS), B) relapse-free survival (RFS), and C) post-progression 
survival (PPS) in colon cancer patients.  The analyses ran on a cohort of 304 (OS), 1045 (RFS), 
and 105 (PPS) patients, respectively.  Patients were split into low or high expression group based 
on the best cutoff between lower and upper quartiles of expression (32, 33).  
 
Next, to test whether SMAD4 inactivation confers resistance to common 
chemotherapeutic agents used for treating colon cancer, we exposed the colon cancer 
model cells to increasing concentrations of 5-FU, irinotecan, or oxaliplatin.  Interestingly, 
SMAD4-negative cells showed significant resistance to 5-FU and irinotecan, but not to 
oxaliplatin (Figure 3).  While resistance to 5-FU has been previously reported by others 




SMAD4-negative compared to SMAD4-positive cells upon exposure to irinotecan, a 





Figure 3: SMAD4-negative colon cancer cells are resistant to 5-FU and irinotecan 
but not oxaliplatin.  
SMAD4+/+ and SMAD4-/- cells were treated with A) 5-FU, B) irinotecan, or C) oxaliplatin, and 
the viability of cells relative to DMSO-treated controls was determined after 72 hours (cell 
viability assay; mean + SD, n = 3).  The concentration at which 50% of growth was inhibited 
(IC50) was calculated using Prism for each drug (IC50 analysis; mean + SD, n = 3; *P < 0.05, 
***P < 0.001). 
 
Mass spectrometry reveals RICTOR as a novel SMAD4 interacting protein in colon 
cancer cells 
 
Several reports have indicated that overexpression of hypoxia-inducible factor 1-
alpha (HIF-1α) is associated with poor prognosis in colon cancer patients (36-38). Our 
previous studies found that one mechanism for the tumor suppressive role of SMAD4 in 
colon cancer is due to its interaction with and inhibition of tumor promoting 
transcriptional activation mediated by HIF-1α to suppress its target gene, VEGF, which 
promotes angiogenesis (27).  These observations suggested that SMAD4 could similarly 
interact with other tumor promoting pathway factors to suppress oncogenic events 
including metastasis and drug resistance.   
 
To dissect the SMAD4 interactome, we elected to use FLAG-tagged SMAD4 to 




FLAG-SMAD4 overexpression plasmid and confirmed that the FLAG-SMAD4 protein 
was functional based on the ability to induce expression of the luciferase reporter gene 
downstream of a SMAD-binding element (SBE4) in response to TGFβ treatment (Figures 
4A & B).  In addition, overexpression of FLAG-SMAD4 led to suppression of the 
luciferase reporter gene down stream of VEGF promoter as well as decreased invasion in 
the colon cancer cells, further confirming its tumor suppressive role in colon cancer 






Figure 4: Overexpressed SMAD4 is responsive to TGFβ treatment.  
A, Overexpression of FLAG-tagged SMAD4 in SMAD4-/- cells was monitored using western 
blotting.  B, Cells were transfected with SBE4-luciferase reporter plasmid for 72 hours, serum-
starved overnight, and treated with 5ng/ml of TGFβ for 4 hours prior to lysis (RLU, relative 
luminescence unit; mean + SD, n = 3; ***P < 0.001).  C, Cells were transfected with 
VEGFpromoter-luciferase reporter plasmid for 72 hours, serum-starved overnight, and treated 
with 5ng/ml of TGFβ for 4 hours prior to lysis (RLU, relative luminescence unit; mean + SD, n = 
3; ***P < 0.001).  D, Cells were serum-starved and seeded on transwells and allowed to cross the 
membrane coated with Matrigel for 24 hours (transwell invasion; RFU, relative fluorescence unit; 
mean + SD, n = 3; *P < 0.05).  
 
Next, immunoprecipitation (IP) of the FLAG-SMAD4 protein complexes was 
performed followed by mass spectrometry (MS) and Mascot protein database search, 
revealing 1200 protein hits.  These protein candidates were then subjected to 




background contaminants.  Protein hits that are enriched more than 5 times in spectral 
count compared to the control sample were then subjected to Ingenuity Pathway analyses 
(Table 3).   Interestingly, three members of the mTORC2 complex, mTOR, RICTOR, and 
TELO2, were among the proteins bound by SMAD4 (Figure 5) (39, 40).  Therefore, we 
predicted that this complex is of functional relevance and decided to focus on the novel 






Table 3: List of 182 SMAD4-interacting candidates subjected to IPA for direct 
protein-protein interaction analysis. 
AARSD1, ABCC1, ABHD10, ACADSB, ACOX1, AKAP11, ALDH1A3, ANAPC7, AP1G1, 
AP3M2, ARAP1, ARFGEF1, ARFIP1, ARHGAP18, ARHGAP29, ARPC1B 
ASCC2, ASMTL, ATP5I, BAX, CAPG, CDC42BPG, CDH3, CDK5RAP3, CNDP2, CPD, 
CPT2, CYB5B, CYP24A1, DAD1, DCAF8, DDRGK1, DIS3L2, DMKN, DNAJC2, DNAJC3, 
DNMBP, DOCK1, DOCK6, DPCD, DPP7, EARS2, EHD1, EIF2AK4, ELP2, EML3, EPS8L2, 
ERCC6L, EXOC2, EXOC6B, EXOC8, FDXR, FERMT1, FLAD1, FOXRED1, FYCO1, GAA, 
GBE1, GIT1, GLMN, GNL1, GNPDA1, GPD2, GRIPAP1, GSS, GTPBP10, GUF1, HDAC6, 
HEATR6, HECTD3, HECTD4, HERC4, HIP1R, HK2, HMGCS2, HSPA14, INPPL1, ITCH, 
ITGA3, ITGA6, KIAA0196, KIF3B, KLC3, LAMB2, LARS2, LLGL2, LPIN2, LRCH3, LSR, 
MAGT1, MALT1, MAP1S, MARK2, METAP1, MLLT11, MRPL18, MRPL43, MRPL50, MT-
ND2, MTIF2, MTMR14, MTOR, MTR, MUT, NCSTN, NDUFV1, NEMF, NFS1, NLRP2, 
OGFR, OSBPL11, OSTC, PAIP1, PARP4, PCYOX1L, PDCL3, PDE12, PDXDC1, PDZD8, 
PFKFB2, PGM2, PGM3, PIK3R2, PKN1, PKP3, PLXNB2, PPFIBP1, PREP, PRKAA1, 
PRPF39, PSME4, PTGES2, PTGFRN, PTK2, PTK7, RICTOR, RIOK2, RNPEP, S100A2, 
SEC24A, SKI, SLC38A10, SLC9A3R1, SMAD4, SMAD9, SMG8, SNX5, SOGA1, SORD, 
SPR, SRGAP2, ST14, STAT2, STRN, SUCLG2, SUPV3L1, SYPL1, TBRG4, TELO2, 
TFCP2L1, THNSL1, TICAM2, TRAF6, TRAPPC8, TRIM72, TRIP10, TST, TUBGCP6, TWF2, 
TXNRD1, UBA6, UBE3A, UBE3C, UBE4A, UBE4B, UBQLN1, UQCRB, USP19, USP24, 








Figure 5: Mass spectrometry analysis of SMAD4 protein complexes reveals novel 
SMAD4-interacting partners. 
FLAG-SMAD4 protein complexes were immunoprecipitated from cell lysates and identified 
using mass spectrometry and Mascot database search.  Schematic shows our strategy for the 
selection of candidate for downstream functional characterization.  RICTOR, which is unique to 
mTORC2, was selected as the top candidate targeted by SMAD4.   
 
While mTOR and TELO2 are common to both mTORC1 and mTORC2, RICTOR 
is unique to mTORC2, which activates AKT, an oncogene involved in promoting 
survival, via phosphorylation on serine 473 (41, 42).  In light of this, we anticipated that 
RICTOR could be a major mediator for chemoresistance and selected it for functional 
characterization and as a potential target for therapeutic intervention in SMAD4-negative 
colon cancer.  We followed up with MS data and confirmed that SMAD4 interacts with 




RICTOR is dependent upon TGFβ mediated downstream effects, we performed western 
blot analysis of the SMAD4 protein complexes formed in the presence or absence of 
TGFβ.  Interestingly, this interaction appeared to be independent of TGFβ stimulation, 
indicating that SMAD4 may have other non-canonical roles in suppressing colon cancer 




Figure 6: The interaction between SMAD4 and RICTOR in colon cancer cells is 
TGFβ-independent.  
A, The presence of phospho-SMAD2, a known SMAD4-interacting protein, and RICTOR, a 
novel SMAD4-interacting candidate, was determined in FLAG-SMAD4 complexes using western 







B, Colon cancer cells were serum-starved and treated with or without 5ng/ml of TGFβ prior to 
cell lysis and co-immunoprecipitation.  Western blotting shows the relative levels of RICTOR in 
FLAG-SMAD4 complexes with or without TGFβ treatment.  
 
 
SMAD4-negative colon cancer exhibits hyperactivation of mTORC2/AKT pathway  
 
To better understand whether mTORC2 is a major contributor to chemoresistance 
in SMAD4-negative colon cancer, we first assessed the activation status of mTORC2 
pathway by examining the level of phospho-AKTS473, a downstream oncogenic target 
activated by mTORC2.  We found that SMAD4-negative cells displayed pronounced 
phospho-AKTS473 levels compared to SMAD4-positive cells, consistent with the notion 
that SMAD4 may play a role in suppressing this pathway (Figure 7A) (28).  In line with 
these observations, SMAD4-negative cells were highly sensitive to AKT inhibition, 
indicated by significantly reduced viability upon treatment with MK2206, an allosteric 





Figure 7: SMAD4-negative colon cancer cells exhibit hyper AKT signaling activity 
and sensitivity to MK2206. 
A, Western blotting shows the relative levels of phospho-AKTS473 in SMAD4+/+ and SMAD4-/- 
cells.  B, SMAD4+/+ and SMAD4-/- cells were treated with MK2206, an allosteric AKT inhibitor, 
for 72 hours (cell viability assay; mean + SD, n = 3).  C, The IC50 of MK2206 in each cell line 




Next, to elucidate if restoration of SMAD4 could be directly involved in 
inhibiting RICTOR-mediated downstream signaling, we assessed the level of phospho-
AKTS473 in colon cancer cells overexpressing FLAG-SMAD4.  We found that SMAD4 
overexpression resulted in suppressed levels of phospho-AKTS473, which serves as a 
functional readout of mTORC2 pathway activation (Figure 8A).  Importantly, SMAD4 
overexpression resulted in enhanced sensitivity of the colon cancer cells to irinotecan, 
with a corresponding increase in the levels of the apoptotic marker, cleaved caspase 3 
(Figures 8B & C).  Overall, these data suggested that SMAD4 deletion in colon cancer 
might lead to uninhibited mTORC2/AKT signaling activity, thereby promoting resistance 








Figure 8: Overexpression of SMAD4 suppresses AKT signaling and sensitizes colon 
cancer cells to irinotecan by promoting apoptosis. 
A, Western blotting shows the levels of p-AKTS473 in cells overexpressing SMAD4.   B, The 
indicated cell lines were treated with irinotecan (10µM) for 72 hours.  Viability of cells was 
normalized to DMSO-treated controls  (cell viability assay; mean + SD, n = 3; *P < 0.05).  C, 
Western blotting shows the levels of cleaved caspase 3 in the indicated cell lines after treatment 
with irinotecan (50µM) for 18 hours. 
 
Depletion of RICTOR suppresses AKT signaling activity and increases sensitivity of 
SMAD4-negative colon cancer cells to irinotecan 
 
To determine whether RICTOR is critical to mTORC2 functionality in SMAD4-
negative colon cancer, we knocked down RICTOR and assessed the expression level of 
phospho-AKTS473 (Figure 9A).  We noticed a dramatic decrease in phospho-AKTS473 




kinase function of mTORC2 required for activating AKT signaling pathway in our model 





Figure 9: Knockdown of RICTOR suppresses AKT signaling in SMAD4-negative 
colon cancer cells.   
A, RICTOR depletion in SMAD4-negative colon cancer cells using shRNA was measured by 
RT-qPCR (RT-qPCR; mean + SD, n = 3; ***P < 0.001).  B, Western blotting shows the levels of 
RICTOR and p-AKTS473 in the indicated cell lines.   
 
In addition, we observed that knockdown of RICTOR increased sensitivity of 
SMAD4-negative colon cancer cells to irinotecan (Figure 10A).  Corresponding to 
RICTOR and phospho-AKTS473 depletion, the cells also displayed higher levels of 




signaling drives resistance to irinotecan by blocking apoptosis (Figure 10B).  
Interestingly, depletion of RICTOR in SMAD4-negative cells also impaired their 
migratory ability, suggesting that RICTOR could serve as a potential therapeutic target to 





Figure 10: RICTOR depletion enhances sensitivity of SMAD4-negative colon cancer 
cells to irinotecan by promoting apoptosis.   
A, The indicated cell lines were treated with irinotecan (10µM) for 72 hours.  Viability of cells 
was normalized to DMSO-treated controls  (cell viability assay; mean + SD, n = 3; **P < 0.01).  
B, Western blotting shows the relative levels of cleaved caspase 3 in the indicated cell lines after 






Figure 11: RICTOR knockdown suppresses migration in SMAD4-negative colon 
cancer cells. 
Cells depleted of RICTOR were serum starved and seeded on transwells and allowed to cross the 
membrane for 24 hours (transwell migration; RFU, relative fluorescence unit; mean + SD, n = 3; 
***P < 0.001). 
 
Despite the correlation between functional activation of mTORC2 pathway and 
malignant progression of colon cancer in SMAD4-negative cells, we wondered if overall 
levels of RICTOR or AKT could predict survival differences in all patients with colon 
cancer irrespective of their SMAD4 status.  Interestingly, we found that, overall, higher 
levels of RICTOR or AKT could predict worse prognosis of colon cancer patients 






Figure 12: High RICTOR expression correlates with worse survival in colon cancer 
patients. 
In silico Kaplan-Meier analyses showing the correlation between RICTOR (probe 228248_at) 
expression and A) overall survival (OS), B) relapse-free survival (RFS), and C) post-progression 
survival (PPS) in colon cancer patients.  The analyses ran on a cohort of 304 (OS), 1045 (RFS), 
and 105 patients (PPS), respectively.  Patients were split into low or high expression group based 







Figure 13: High AKT1 expression correlates with worse survival in colon cancer 
patients. 
In silico Kaplan-Meier analyses showing the correlation between AKT1 (probe 207163_s_at) 
expression and A) OS, B) RFS, and C) PPS in colon cancer patients.  The analyses ran on a 
cohort of 550 (OS), 1211 (RFS), and 141 patients (PPS), respectively.  Patients were split into 
low or high expression group based on the best cutoff between lower and upper quartiles of 




Targeting AKT with MK2206 sensitizes SMAD4-negative colon cancer cells to 
irinotecan 
 
Since there are no drugs that specifically target RICTOR and mTORC2 (43), we 
hypothesized that inhibiting their downstream effector target AKT could restore 
sensitivity of SMAD4-negative colon cancer cells to irinotecan.  Unlike the mTOR 
inhibitor sirolimus, the addition of MK2206 was able to drastically deplete the level of 
phospho-AKTS473 in a manner similar to RICTOR knockdown (Figure 14).  This 
evidence is again consistent with the idea that mTORC2 pathway activation is the 
primary mediator of AKTS473 phosphorylation in these cells, and suggested that mTORC2 




Figure 14: MK2206, but not sirolimus, suppresses p-AKTS473 levels in SMAD4-




Western blotting shows the relative levels of p-AKTS473 in SMAD4-negative cells after treatment 
with MK2206 (1µM) or of sirolimus (10µM), an mTOR inhibitor, for 24 and 48 hours.  
 
Subsequently, we found that the combination of MK2206 and irinotecan was able 
to suppress the viability of SMAD4-negative HCT116 cells two-fold more effectively in 
vitro than irinotecan alone, on par with the sensitivity observed in SMAD4-positive cells 
treated with irinotecan alone (Figure 15A).  Moreover, the addition of MK2206 also 
induced higher levels of cleaved caspase 3 in the presence of irinotecan, further 
supporting that AKT activation is a major driver of resistance to irinotecan-mediated 







Figure 15: Targeting AKT with MK2206 sensitizes SMAD4-negative colon cancer 
cells to irinotecan by induction of apoptosis.   
A, SMAD4-positive and negative cells were treated with MK2206 (1µM), irinotecan (1µM), or 
both for 72 hours (cell viability assay; mean + SD, n = 3; **P < 0.01).  B, The levels of cleaved 
caspase 3 were determined in SMAD4-positive and negative cells after treatment with MK2206 
(1µM), irinotecan (50µM), or both for 18 hours.  
 
Next, we examined another SMAD4-negative colon cancer cell line model, 
SW403, for its response to MK2206 and irinotecan combination treatment.  Interestingly, 
we found that the SW403 cells displayed relatively high phospho-AKTS473 expression as 
predicted (Figure 16A) and exhibited suppression of viability upon combination 










Figure 16: Additional model of SMAD4-negative colon cancer. 
A, The levels of p-AKTS473 and SMAD4 in SW403 cells were determined using western blotting.   
B, SW403 cells were treated with MK2206 (1µM), irinotecan (1µM), or both for 72 hours (cell 
viability assay; mean + SD, n = 3; *P < 0.05, ***P < 0.001).  C, The levels of cleaved caspase 3 
after treatment with MK2206 (1µM), irinotecan (50µM), or both for 18 hours were monitored in 
SW403 cells using western blotting. 
 
Having demonstrated the effects of drug treatment in vitro, we next examined the 
efficacy of the anti-tumor activities of combination therapy in vivo using nude mice 
harboring HCT116 SMAD4-/- xenograft tumors.  The tumor bearing mice were 
randomized to receive vehicle, MK2206, irinotecan, or a combination of MK2206 and 
irinotecan.  Compared to single agents, we found that the combination treatment was the 







Figure 17: Combination treatment with MK2206 suppresses growth of SMAD4-
negative xenografts. 
A, HCT116 SMAD4-/- xenografts in nude mice were treated with vehicle (n = 4), MK2206 
(360mg/kg, n = 4), irinotecan (20mg/kg, n = 5), or a combination of MK2206 and irinotecan (n = 
5).  Tumors were monitored twice a week using a caliper for 30 days (relative tumor volume; 
mean + SD, *P < 0.05).  Representative images of tumors at the end of the experiment are shown. 







Despite an exponential increase in our knowledge base on the identity of genetic 
alterations in colon and other cancers, delivering precision medicine has lagged behind 
due to the difficulties in pinpointing biological targets that become functionally active in 
the various tumor types. SMAD4 mutation or loss of expression, which occurs frequently 
in late-stage colon cancer (13-16), correlates with poor OS, RFS and PPS (Figure 2). 
Interestingly, several studies reported loss of SMAD4 functionality corresponded to 
resistance to 5-FU in the clinic, a standard first-line treatment for the disease (27, 28).  
Although 5-FU resistance has been associated with SMAD4-defective colon cancers, the 
applicability of this resistance phenomenon to other standard chemotherapeutics, such as 
oxaliplatin and irinotecan as well as potential biological targets for inhibition to enhance 
the therapeutic benefit, has remained elusive.  Here, we report that while SMAD4-
negative colon cancer exhibits resistance to both 5-FU and irinotecan, sensitivity to 
oxaliplatin is unaffected by the SMAD4 status. 
 
On the contrary to blinded use of inhibitors to common oncogenic signaling 
pathways, such as MEK-ERK, p38-MAPK, and AKT, with uncertain therapeutic benefit 
for colon cancer patients, here we present an attempt to identify specific biological targets 
to sensitize chemoresistant SMAD4-negative colon cancer to reap the maximum benefit 
with minimal side effects (27, 28).  Previously, our group reported that SMAD4 interacts 




that promotes angiogenesis (27).  Based on these observations, we hypothesized that 
SMAD4 may also act by regulating other critical protein factors involved in conferring 
resistance to chemotherapeutic agents such as irinotecan.  Mass spectrometry analysis 
revealed candidate proteins bound by SMAD4, including mTOR and TELO2, both of 
which are common in mTORC1 and mTORC2, as well as RICTOR, which is only found 
in mTORC2, a protein complex that primarily phosphorylates and fully activates the 
oncogene AKT at Serine 473 (39).  Interestingly, phospho-AKTS473 levels are 
downregulated when SMAD4 is overexpressed, suggesting that SMAD4 is negatively 
regulating RICTOR to prevent mTORC2 from activating the oncogenic AKT.   
 
Because the activation of AKT on Serine 473 has been shown to promote colon 
cancer cell migration and antagonizes apoptosis (42, 43), we decided to characterize the 
role of RICTOR, which is unique to mTORC2, in SMAD4-negative colon cancer.  
Indeed, we found that RICTOR depletion not only impairs AKT signaling and cell 
migration but also sensitizes the cells to irinotecan.  Interestingly, Kaplan-Meier analyses 
also revealed that high RICTOR/AKT1 expression, independent of the SMAD4 status, 
significantly correlated with worse OS, RFS and PPS in colon cancer patients, indicating 
the roles of these two genes in promoting disease progression and thus could serve as 
potential therapeutic targets (Figures 12 & 13). 
 
While RICTOR is a critical component of mTORC2 in activating AKT, there are 




mTORC2 signaling activity in SMAD4-negative colon cancer, we opted to block its 
effector target AKT using the commercially available drug, MK2206, currently being 
tested in multiple clinical trials 
(https://clinicaltrials.gov/ct2/results?cond=&term=MK2206&cntry=&state=&city=&dist
=).  We found that SMAD4-negative colon cancer cells are more sensitive to MK2206 
treatment compared to SMAD4-positive cells, and that MK2206 can further suppress the 
growth of SMAD4-negative cells in the presence of irinotecan.  These findings were also 
confirmed in xenograft models derived from SMAD4-negative colon cancer cells, where 
more dramatic tumor suppression was observed with the combination treatment.  
Interestingly, we also found that the use of MK2206 with irinotecan could significantly 
enhance suppression of the viability of SMAD4-negative pancreatic cancer cell lines 
(ASPC1, CFPAC1) displaying active AKT signaling in vitro, suggesting that the 
combination therapy could be of general applicability for cancers exhibiting loss of 
SMAD4 (Figure 18). Additionally, we also noted that high RICTOR or AKT expression 
corresponded significantly to poor overall survival (OS) in pancreatic cancer patients, 








Figure 18: SMAD4-negative pancreatic cancer cells show enhanced sensitivity to 
irinotecan with the addition of MK2206. 
A, The levels of p-AKTS473 in SMAD4-negative ASPC1 and CFPAC1 pancreatic cancer cells 
were determined using western blotting.  B, ASPC1 and CFPAC1 cells were treated with 
MK2206 (1µM), irinotecan (1µM), or both for 72 hours (cell viability assay; mean + SD, n = 3; 






Figure 19: High RICTOR/AKT levels correlate with worse prognosis in pancreatic 
cancer. 
In silico Kaplan-Meier analyses showing the correlation between SMAD4, RICTOR, or AKT1 
expression and overall survival (OS) in pancreatic cancer patients.  The analyses ran on a cohort 
of 87 patients.  Patients were split into low or high expression group based on the best cutoff 





In conclusion, our observations suggest that overactivation of the mTORC2 
pathway, which has been associated with poor survival in a growing number of cancers 
(44), may be the driver of resistance to irinotecan-mediated apoptosis and that targeting 
RICTOR or downstream effectors such as AKT may serve to enhance the sensitivity of 
SMAD4-negative colon cancer cells to irinotecan.  We report here for the first time that 
SMAD4 interacts with RICTOR to suppress mTORC2 functionality and therefore the 
loss of SMAD4 function results in oncogenic activation of the mTORC2 pathway, 
leading to enhancement in malignant colon cancer progression and resistance to 
chemotherapeutic agents such as irinotecan (Figure 20).  Interestingly, our studies also 
found that overexpression of RICTOR or AKT could serve as biomarkers for poor 
prognosis, independently of the SMAD4 status.  Overall, we suggest that design of 
therapies involving chemotherapeutic agents such as irinotecan might be highly effective 
when combined with targeted inhibitors for RICTOR/AKT when the colon cancer cells 








Figure 20: Working model 
Our findings suggest that SMAD4 inactivation leads to uninhibited mTORC2/AKT signaling 







The results presented in this chapter of the dissertation give rise to many 
questions about the role of the mTORC2 pathway as a therapeutic target in colon cancer, 
which may be further explored experimentally:  
 
1. Is an overactive mTORC2 pathway able to promote resistance to irinotecan in 
sensitive colon cancer? 
Our experiments have shown that depletion of RICTOR or pharmacological 
inhibition of AKT can sensitize SMAD4-negative colon cancer cells to irinotecan.  
It would be necessary to determine if SMAD4-positive cells that are initially 
sensitive to the treatment could acquire resistance through the activation of the 
mTORC2 pathway.  This could be accomplished by overexpressing RICTOR in 
colon cancer cells with intact SMAD4 via viral transduction and determine if 
phospho-AKTS473 level increases.  Alternatively, introduction of constitutively 
active, myristoylated AKT in SMAD4-positive cells through viral transduction 
could be performed to achieve high levels of phospho-AKTS473.  Cells with 
overactive mTORC2 pathway would then be exposed to irinotecan to determine if 
viability is enhanced compared to control cells. 
 
2.  How does AKT signaling mediate resistance to irinotecan-mediated cell death? 
Our experiments indicated that the levels of cleaved-caspase 3 in colon cancer 




targeting AKT could induce apoptosis.  Nevertheless, how AKT is preventing 
irinotecan-mediated apoptosis in the first place remains elusive.  It would be 
informative to elucidate the mechanisms of AKT in suppressing cell death by 
comparing the levels of its downstream targets, such as BAD, in SMAD4-
negative colon cancer cells with SMAD4 overexpression or RICTOR depletion 
(41).  
 
3.  How does SMAD4 affect the assembly and signaling of mTORC2 in colon cancer?  
Our experiments have shown that SMAD4 interacts with RICTOR in vitro.  It 
would be informative to determine if the assembly of the mTORC2 complex is 
compromised in the presence of SMAD4, which could be accomplished by 
pulling down mTOR and determine if RICTOR is diminished in the precipitate. It 
would also be critical to determine if the activity of other mTORC2 effector 
targets, such as SGK, is affected in the presence of SMAD4, and if targeting those 
molecules could also improve sensitivity to irinotecan (42).   
 
4.  What is the role of RICTOR in metastasis in colon cancer? 
Since we hypothesized that RICTOR is targeted for metastatic suppression by 
SMAD4, it would be necessary to determine if depletion of RICTOR affects 
metastatic potential of colon cancer cells in mouse orthotopic models.  This could 
be accomplished by surgically xenografting shRICTOR tumorspheres into the 




cells overtime.  If targeting RICTOR could impair metastasis in vivo, the next step 
would be screening for small molecules that binds to RICTOR to prevent it from 








MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-




Breast cancer is the most lethal non-smoking related cancer amongst women in 
the United States, with more than 40,000 deaths estimated to occur in 2018 (1).  
Therapies have been developed to target three major cell-surface receptors, namely 
estrogen receptor (ER), progesterone receptor (PR), and HER2, which are well-
established biomarkers and promoters of breast cancer growth and progression (3, 4).  
However, these targeted therapies are not effective against triple-negative breast cancer 
(TNBC) due to the lack of the three receptors in this disease subtype (5).  Despite 20%-
30% discordance based on gene expression patterns between basal-like breast cancer 
(BLBC) and TNBC, due to lack of expression of ER, PR and the HER2 genes in these 
two definitions, both receive the same standard guide to personalized medicine (45-48). 
Accounting for 10-20% of breast cancers, TNBC is highly prevalent in young 
premenopausal African-American women (49-51).  A minority (15%) of TNBC patients 
responds well to chemotherapy, however those with residual diseases are more likely to 
die from tumor recurrence and metastasis, partly due to the lack of effective therapies 




to improve survival as well as reduce health outcome disparity between TNBC and non-
TNBC.   
 
Epithelial-mesenchymal transition (EMT) is a transcriptional program essential 
during embryonic development and for maintaining tissue homeostasis, where stationary 
cells acquire mobility to migrate and form new tissues (53).  It has been shown to play a 
pivotal role in the early stage of metastasis, where primary tumor cells hijack this 
program to invade local tissues and intravasate to the bloodstream, thereby initiating the 
progression of the disease from non-malignant to malignant stage.  Moreover, EMT has 
been shown to confer tumor-initiating properties in tumor cells, which is the foundation 
of heterogeneity in the cell population that contributes to resistance to therapy.  
Importantly, incomplete eradication of residual tumor-initiating cells has been described 
as a major source of disease relapse (54-56).  Hence, there is a critical need to dissect the 
molecular mechanisms of EMT program in TNBC cells and design targeted therapeutic 
strategies to prevent disease progression and recurrence. 
 
MicroRNAs (miRNAs) are negative post-transcriptional regulators that inhibit the 
translation of one or more target mRNAs, thereby changing the proteome and exerting 
significant effect on cellular functions (57).  The mature ~22nt product of the small 
noncoding RNA species binds predominantly to the 3’UTR of their mRNA targets 
through a complementary seed region, sometimes leading to the degradation of the 




potentially be delivered therapeutically to tumor cells to inhibit the expression of target 
oncogenes and suppress cancer progression (59, 60).   
 
Here, we report that miR-4417 is a novel tumor-suppressive miRNA in which its 
expression level decreases during progression of TNBC from nonmalignant to the 
malignant stage.  miR-4417 is localized to a deletion hotspot on chromosome 1p36, 
which potentially harbors a tumor suppressor gene, and its expression is low in 
mesenchymal TNBC cells compared to epithelial cells.  Finally, overexpression of miR-
4417 impairs migration and tumorigenicity of TNBC cells in vitro, suggesting the 
therapeutic benefit of miR-4417 as a tool against TNBC.   
 
Materials and methods 
	
Cell culture 
MDA-MB-231-LM2 (LM2) and MDA-MB-231–BoM2 (BoM2) cells were a generous 
gift from Dr. Joan Massague.  MDA-MB-231, MDAM-MB-543, UACC812, SUM149, 
and SUM159 cells were obtained from ATCC.  MIII, MIV, and NeoT cells (61) were 
cultured in DMEM/F12 medium supplemented with 5% Horse Serum (HS), 1% 
antibiotics, 10 mg/ml Insulin, 20ng/ml epidermal growth factor, 100ng/ml cholera toxin, 
and 500ng/ml hydrocortisone.  MDA-MB-231, MDAM-MB-543, UACC812, LM2, and 
BoM2 cells were maintained in DMEM medium containing 10% FBS, while SUM149 
and SUM159 cell lines were cultured in Ham's F/12 containing 5% FBS, 10mg/mL 




medium (Stem Cell Technologies) supplemented with 0.48mg/mL hydrocortisone and in 
the presence of 1% methylcellulose (62).  All cells were grown in the presence of 1% 
penicillin/streptomycin in a humidified incubator at 37°C with 5% CO2.  
 
Kaplan-Meier survival analysis 
A database of breast cancer patients was established as described previously (63-65).  
Survival curves were generated based on the transcript level of a candidate gene using the 
Cox proportional hazards regression analysis and plotting Kaplan-Meier plots as 
described.  A p-value below 0.05 was accepted as a significant correlation between gene 
expression and survival. 
 
shRNA cloning and stable gene knockdown 
shRNA oligonucleotides were annealed and ligated to pLKO.1 lentiviral expression 
vector.  The correct shRNA sequence was confirmed by sequencing.  The pLKO.1 
vector, psPAX2 and pMD2.G packaging vectors, and Xtreme-Gene transfection reagent 
(Roche) were then mixed in OptiMEM (Life Technologies) and added to to HEK293 
cells for 48 hours.  Viral medium was run through 0.45µm filters and added to target cells 
for 24 hours in the presence of 10µg/ml polybrene.  Cells were then fed with fresh media 







Table 4: Sequence of shRNA oligonucleotides ligated into pLKO.3G plasmid. 
shSCR: 
F: 5’AATT CCTAAGGTTAAGTCGCCCTCG CTCGAG 
CGAGGGCGACTTAACCTTAGG TTTTTTAT 
R: 5’ AAAAAAA CCTAAGGTTAAGTCGCCCTCG CTCGAG 
CGAGGGCGACTTAACCTTAGG 
shDICER: 
F: 5’	AATTGGAAGAATCAGCCTCGCAACA CTCGAG 
TGTTGCGAGGCTGATTCTTCC TTTTTTAT 
R: 5’ AAAAAA GGAAGAATCAGCCTCGCAACA CTCGAG 
TGTTGCGAGGCTGATTCTTCC 
 
Reverse Transcription-quantitative PCR (RT-qPCR) 
Total RNA was isolated from cells using Trizol (Life Technologies) and Direct-zol RNA 
Miniprep kit (Zymo Research).  For mRNA, total RNA was converted to cDNA using 
Super Script III Reverse Transcriptase (Life Technologies).  The cDNA samples were 
then mixed with Power SYBR Green PCR Master Mix and qPCR primers, and run on 
7900HT Real-Time PCR system to quantify expression level of target genes.   
 














F: AGGTGGACCAGCTA ACCAAC 
R: AGCATCTCCTCCTGCAATTT 
β-ACTIN: F: CGAGCACAGAGCCTCGCCTTTGCC  
R: TGTCGACGACGAGCGCGGCGATAT 
 
For miRNA, total RNA was converted to cDNA using TaqMan™ MicroRNA Reverse 
Transcription Kit (Life Technologies).  The cDNA samples were then mixed with 
TaqMan™ Universal PCR Master Mix II, no UNG (Life Technologies) and TaqMan™ 
Small RNA Assay (Life Technologies), and run on 7900HT Real-Time PCR system to 
quantify expression level of target miRNAs.  RNU6 was used for normalization of the 
miRNA expression data.      
 
Western blotting 
Cells were lysed with RIPA buffer (Pierce) in the presence of protease and phosphatase 
inhibitors (Roche).  Protein lysates were then scraped from the dish using cell lifters and 
centrifuged for 15 minutes at 14,000g at 4°C.  Protein supernatant was mixed with 
4xLDS buffer and 10x reducing agent before being loaded onto NuPAGE 4-12% pre-cast 
gels and separated for 2 hours at 100V.  Proteins were then transferred to a PVDF 
membrane overnight at 4°C.  The membrane was blocked with 5% milk for 30 minutes at 




membrane was washed with TBS-T for 5 minutes three times and incubated with 
secondary antibodies for 1 hour at room temperature.  Membranes were washed with 
TBS-T for 5 minutes three times and incubated with enhanced chemiluminescence agent.  
Films were used for the visualization of protein bands of interest.  Antibodies used were 
as follows: SMAD2, E-cadherin, vimentin, phosopho-p38Thr180/Tyr182, and total p38 from 
Cell Signaling Technology; ACTIN from Sigma-Aldrich. 
 
Microarray analysis 
Total RNA was isolated from cells using Trizol (Life Technologies) and the miRNeasy 
Mini kit (Qiagen).  The quality of RNA was determined using an Agilent Bioanalyzer 
2100 and small RNA samples with an RNA Integrity Number (RIN) > 8 were hybridized 
to Affymetrix GeneChip miRNA v4.0 microarrays.  Raw Affymetrix CEL files were 
normalized to produce probeset-level expression values for all human and control 
probesets using Affymetrix Expression Console (version 1.3.0.187), using the Robust 
Multiarray Average (RMA) (66) and Detection Above BackGround (DABG).  Analysis 
was limited to the 2,578 human microRNAs interrogated by the array.  Principal 
Component Analysis (PCA) was performed using the 'prcomp' R function with 
expression values that had been normalized across all samples to a mean of zero and a 
standard deviation of one.  Pairwise differential microRNA expression was assessed 
using the moderated (empirical Bayesian) t- test implemented in the limma R package 
(version 3.14.4) (i.e., creating simple linear models with lmFit, followed by empirical 




accomplished using the Benjamini-Hochberg false discovery rate (FDR) (67).  All 
statistical analyses were performed using the R environment for statistical computing 
(version 2.15.1). 
 
Transient transfection with miRNA mimics 
miRNA mimics (Life Technologies) were mixed with Xtreme-Gene transfection reagent 
(Roche) in OptiMEM (Life Technologies) for 5 minutes at room temperature before 
being added drop-wise to target cells.   
 
Transwell migration assay 
Cells were serum-starved overnight, trypsinized, and resuspended in serum-free media.  
The cells were then seeded on transwell permeable supports with 8µm pores (Corning) on 
a 24-well plate.  Cells were allowed to migrate towards serum-containing medium, which 
serves as a chemoattractant, for 24 hours. Migrated cells were then dissociated from the 
basal side of the transwell using Hank’s-based Cell Dissociation Buffer (Life 
Technologies), stained with Calcein-AM (Life Technologies), and quantified using a 
plate reader. 
 
Signaling pathway activity profiling 
Cells seeded in 96-wells were fixed with 4% paraformaldehyde and the levels of target 
proteins spanning 20 pathways were determined using the ActivSignal IPAD platform 





All statistical analyses were performed using the student t-test (two-tailed, type 2).  Error 
bars represent standard deviation.  A p-value below 0.05 was considered statistically 







Microarray expression profiling of an EMT model of TNBC reveals miRNAs 
involved in suppressing malignant progression 
 
To identify potential tumor-suppressive miRNAs in TNBC, we exploited a 
previously established model for TGFβ-regulated early stages of malignancy promoting 
EMT comprised of a pair of isogenic MIII cells with intact or deficient SMAD2 
expression (68).  In silico Kaplan-Meier analyses revealed that the probability of distant 
metastasis-free survival (DMFS) and relapse-free survival (RFS) decreased significantly 
in patients with high levels of SMAD2 expression in BLBC, suggesting that SMAD2 is 
promoting malignancy in this disease subtype by maintaining intact TGFβ-SMAD 







Figure 21: High SMAD2 expression correlates with worse survival in basal-like  
breast cancer. 
In silico Kaplan-Meier analyses shows the correlation between SMAD2 (probe 203077_s_at) 
expression and distant metastasis-free survival (DMFS, HR=1.99 (1.17-3.37), logrank P = 
0.0095), relapse-free survival (RFS, HR = 1.57 (1.22-2.03), logrank P = 0.00046), and overall 
survival (OS, HR = 1.51 (0.92-2.49), logrank P = 0.1) in patients with basal-like breast cancer.  
The analyses ran on a cohort of 232 (DMFS), 618 (RFS), and 241 (OS) patients, respectively. 
Patients were split into low or high expression group based on median expression of the gene 
(63). 
 
Depletion of SMAD2 in MIII cells using shRNA led to a drastic increase in E-
cadherin levels, with a corresponding decrease in vimentin levels, thereby changing the 
morphology of the cells from mesenchymal to more epithelial-like  (Figures 22).  
Importantly, knockdown of SMAD2 also diminished the migratory ability of MIII cells, 
suggesting that tumor-suppressive miRNAs may be upregulated as EMT is reversed 





Figure 22: SMAD2 depletion reverses EMT in TNBC model.  
A, Knockdown of SMAD2 in TNBC cells using shRNA and subsequent changes in CDH1 and 
VIM levels was monitored by RT-qPCR (n=3, *p < 0.05). B, Western blotting shows the relative 





Figure 23: SMAD2 depletion suppresses migration in TNBC cells.  
Representative images showing the closure of the wound in the indicated cell lines after 20 hours 
of incubation.  
 
Next, we subjected MIIIshGFP and shSMAD2 cells to differential miRNA 
expression analysis and identified a list of miRNAs significantly suppressed in the 
malignant cells compared to nonmalignant cells (Figure 24 & 25).  Among these 
miRNAs are miR-200c, miR-200b, and miR-141, which are well-established members of 
the miR-200 family known to suppress EMT, miR-205 (another EMT-suppressor), as 




in breast cancer (69-74).  Interestingly, the fold change of miR-4417 is the highest among 
these differentially expressed miRNAs, suggesting that it is likely to play a critical role in 
suppressing the progression of TNBC cells.   
 
 
Figure 24: Principal component analysis reveals total 25% variance between 
MIIIshGFP vs MIIIshSMAD2 cells. 
PCA showing separation between MIIIshGFP and shSMAD2 cells along PC1, indicating that 






Figure 25: SMAD2 depletion induces the expression of miRNAs that inhibit EMT 
and suppress progression in TNBC cells.   
Unbiased hierarchical clustering of relative miRNA levels in MIIIshGFP and shSMAD2 cells.  




Mesenchymal TNBC cells exhibit low levels of miR-4417 compared to epithelial cells 
 
To verify the changes in miRNA expression level observed from the microarray 
data, we performed RT-qPCR on selected miRNAs and confirmed that miR-4417 and 
miR-200c-3p were highly depleted in malignant MIIIshGFP cells compared to 
nonmalignant shSMAD2 cells.  On the other hand, miR-210-3p is significantly enriched 
in malignant MIIIshGFP cells (Figure 26).  Moreover, the differential expression pattern 
of miR-4417, miR-200c-3p, and miR-210-3p was also similarly observed in another 
established EMT model of TNBC comprised of isogenic LM2pQ (mesenchymal) and 







Figure 26: miR-4417 is suppressed in mesenchymal TNBC cells compared to their 
epithelial counterparts.  
The change in expression levels of the indicated miRNAs was measured in isogenic 
mesenchymal (MIIIshGFP, LM2pQ) and epithelial cells (MIIIshSMAD2, LM2pQSDPR) using 
RT-qPCR (*p < 0.05).  
 
We proceeded to evaluate the expression of miR-4417 in a panel of breast cancer 
cell lines using RT-qPCR and again found that miR-4417 is more highly enriched in 
epithelial cells (NeoT, MIV, UACC812, MDAMB453) but suppressed in mesenchymal 
cells (SUM159, MDAMB231-BoM2, SUM149, MDAMB231), suggesting that low 
expression of miR-4417 may serve as a novel biomarker for malignant progression in 





Figure 27:  miR-4417 is suppressed in mesenchymal breast cancer cells compared to 
epithelial cells.   
The expression level of miR-4417 in a panel of breast cancer cell lines with epithelial or 
mesenchymal morphology was measured using RT-qPCR (*p < 0.05).   
 
Low miR-4417 expression correlates with poor survival in TNBC patients 
 
To determine if miR-4417 expression could predict prognosis in breast cancer, we 
performed Kaplan-Meier analysis using a recently established database (64).  We found 
that the probability of overall survival decreased significantly in TNBC patients with low 
levels of miR-4417, suggesting that miR-4417 is tumor-suppressive and could serve as a 
prognostic biomarker in this disease subtype (Figure 28).  Interestingly, low levels of 
miR-4417 also correlate with worse prognosis in ER-negative, PR-negative, and HER2-
positive breast cancer patients as well as other cancer types, indicating the applicability of 






Figure 28: Low mir-4417 expression correlates with worse prognosis in patients 
with TNBC. 
In silico Kaplan-Meier analysis showing the correlation between high miR-4417 expression and 
overall survival in TNBC, ER-negative, PR-negative, and HER2-positive patients.  Patients were 
split into low or high expression group based on the best cutoff between lower and upper quartiles 





Figure 29: Low mir-4417 expression correlates with worse prognosis in patients 
with specific cancer types. 
In silico Kaplan-Meier analysis showing the correlation between high miR-4417 expression and 
overall survival in patients with the indicated cancer types.  Patients were split into low or high 
expression group based on the best cutoff between lower and upper quartiles of expression (65). 
 
Based on these observations, we hypothesized that miR-4417 acts as a tumor 
suppressor gene and may be inactivated or lost during breast cancer progression.  In silico 
cBioPortal analysis revealed that miR-4417 is lost via deep deletion in a subset of breast 
cancer samples across multiple studies, most notably in the metastatic breast cancer 




1p36, a genomic region associated with high frequency of loss of heterozygosity (LOH) 
in breast, cervical, colon, and thyroid cancers as well as melanoma, further strengthening 
the notion that the novel miRNA plays a tumor-suppressive role in TNBC (78).   
 
 
Figure 30: miR-4417 is lost in a subset of breast cancer samples.   
In silico cBioPortal analysis shows the alteration frequency of miR-4417 across multiple breast 






miR-4417 suppresses migration and tumorigenecity of TNBC cells in vitro 
 
To validate that miR-4417 is a functional miRNA, we first knocked down 
DICER, a critical component in the miRNA biogenesis cascade, in TNBC cells (Figure 
31A).  We observed that miR-4417 expression level diminished when DICER was 




Figure 31:  The biogenesis of miR-4417 is DICER-dependent. 
A, DICER depletion via shRNA in the indicated cell lines was examined using RT-qPCR (*p < 
0.05).  B, The levels of miR-4417 were measured using RT-qPCR upon knockdown of DICER in 






To determine if miR-4417 could suppress malignant phenotypes in TNBC, we 
transfected MIII and SUM159 cells with miR-4417 mimics and found that the migratory 
potential of these cells were significantly diminished (Figure 32).  Because EMT is 
known to confer tumor-initiating properties in cancer cells, we next assessed the ability of 
these TNBC cells to form three-dimensional mammospheres under serum-free conditions 
upon miR-4417 transfection (55).  As expected, TNBC cells overexpressing miR-4417 
exhibited deficiency in forming mammospheres, further indicating that miR-4417 is 
tumor suppressive in TNBC (Figure 33).  Interestingly, signaling pathway activity 
profiling (ActivSignal) revealed phospho-p38 MAPK levels were significantly decreased 
in SUM159 cells overexpressing miR-4417, suggesting that miR-4417 can serve as a 
therapeutic tool to suppress oncogenic pathways and prevent malignant progression 






Figure 32: Overexpression of miR-4417 suppresses migration of TNBC cells in vitro.   
A & B, MIII and SUM159 cells were transfected with negative control (NC) or miR-4417 mimics 
and the level of miR-4417 was monitored using RT-qPCR (*p < 0.05).  C & D, Transfected cells 






Figure 33: Overexpression of miR-4417 suppresses the self-renewal ability of TNBC 
cells in vitro.   
A & B, The number of transfected MIII and SUM159 cells growing as mammospheres under 






Figure 34: Cancer-regulating pathways are suppressed by miR-4417 in TNBC cells. 
A, Signaling pathway profiling reveals phospho-protein levels altered in TNBC cells transfected 
with miR-4417 mimics.  B, Western blotting shows the levels of phospho-p38 MAPK in TNBC 







Gene expression profiling studies have shown that miRNAs are globally 
downregulated in cancer when compared to normal tissues, in part through targeting of 
the miRNA biogenesis pathway, leading to induction of EMT to promote invasion, 
intravasation, and metastasis (79-81).  The miR-200 family, consisting of miR-200a, 
miR-200b, miR-200c, miR-141, and miR-429, is one for the most well characterized 
groups of EMT-suppressing miRNAs.  The members in the family predominantly target 
ZEB1/ZEB2, which are transcriptional repressors of E-cadherin, a hallmark epithelial 
marker (69, 70).  While these miRNAs were implicated in EMT suppression in many 
cancerous and non-cancerous cell types, specific tumor-suppressive miRNAs that inhibit 
progression of TNBC cells remain elusive.   
 
Previously, our group found that intact TGFβ-SMAD2 signaling plays a critical 
role in maintaining the mesenchymal phenotype of TNBC cells through epigenetic 
silencing of the epithelial marker E-cadherin (68).  Here, we show that SMAD2 
deficiency not only led to re-expression of E-cadherin but also impaired the migratory 
ability of these cells.  We decided to exploit this EMT model to identify specific miRNAs 
that could inhibit TNBC.  Differential expression analysis revealed a list of putative 
tumor-suppressive miRNAs significantly downregulated in malignant TNBC cells, 
including the novel miR-4417 with unknown function during TNBC progression.  




suppressed in cells with mesenchymal morphology when compared to those with 
epithelial morphology, suggesting that the miR-4417 is downregulated to promote cancer 
progression.    
 
Because DICER has been reported to play a tumor suppressive role in breast 
cancer (80, 81), we sought to determine if the biogenesis of miR-4417 is dependent on 
this miRNA-processing protein.  We found that the levels of miR-4417 decreased upon 
depletion of DICER, suggesting that miR-4417 processing is DICER-dependent and its 
expression may be indirectly suppressed when DICER is lost during TNBC progression.  
Interestingly, miR-4417 is localized to 1p36, an LOH hotspot in cancer potentially 
harboring a tumor suppressor gene (78).  Furthermore, miR-4417 is deleted in a subset of 
breast cancer samples, suggesting that the miRNA locus could be directly inactivated to 
promote breast cancer progression (Figure 30).  Importantly, low level of miR-4417 
correlates with worse survival in TNBC patients, which is similarly observed with that of 
miR-200c (Figure 35), suggesting that these miRNAs could serve as prognostic 





Figure 35: Low miR-200c expression correlates with worse survival in patients with 
TNBC. 
In silico Kaplan-Meier analysis showing the correlation between high miR-200c expression and 
overall survival in all breast cancer (HR = 0.69 (0.47-1.02), logrank P = 0.063) or TNBC patients 
(HR = 0.21 (0.07-0.61), logrank P = 0.0016).  The analysis ran on a cohort of 1061 and 97 
patients respectively.  Patients were split into low or high expression group based on the best 
cutoff between lower and upper quartiles of expression (64). 
 
Based on these observations, we hypothesized that miR-4417 plays a tumor 
suppressive role in TNBC.  Delivery of miR-4417 mimics to TNBC cells significantly 
suppressed their migratory and self-renewal abilities, indicating that the miRNA exerts 
tumor-suppressive effects.  Moreover, it appears that miR-4417 overexpression could 
significantly suppress the phosphorylation of proteins involved in cancer-regulating 




analyzed the gene targets of miR-4417 predicted by TargetScan, miRDB, and Ingenuity 
Pathway Analysis (IPA) and identified 27 common targets using these three algorithms 
(Figure 36).  Canonical pathway analysis of these 27 common targets using IPA revealed 
that TAB2 and MAPT were involved in p38 MAPK signaling, which has been reported 
to activate NF-κB and promote drug resistance and EMT in breast cancer  (Figure 37) 
(82, 83).  Therefore, we hypothesize that miR-4417 may be targeting TAB2 for 
degradation as it has been recently reported (84), potentially resulting in the impairment 
of downstream p38 MAPK signaling as observed in our TNBC model (85).  However, 
follow-up experiments should be performed to explore the interaction between miR-4417 
and p38 MAPK as well as other pathways in vitro and define their respective roles in 







Figure 36: The 27 common gene targets of miR-4417 predicted using TargetScan, 





Figure 37: Ingenuity Pathway Analysis reveals pathways enriched with the 27 
common gene targets of miR-4417. 
 
In conclusion, our findings suggest that miR-4417 expression is suppressed in 
TNBC cells undergoing EMT, which is a critical event during the early stage of 
metastasis.  In addition, low expression of miR-4417 correlates with poor survival in 
patients with TNBC as well as other disease subtypes, suggesting the value of miR-4417 




role in TNBC, as shown by the impaired migratory and tumor-initiating properties in 
TNBC cells upon introduction of miR-4417 mimics, indicating its potential utility for 






1. What are the mRNA targets of miR-4417 in TNBC? 
It would be critical to identify the mRNA targets of miR-4417 in TNBC cells to 
elucidate the mechanisms of tumor suppression by the miRNA.  This could be 
accomplished by performing microarray analysis to profile the transcriptome of 
cells transfected with miR-4417 mimics.  The identified suppressed transcripts 
could then be compared with the list of in silico predicted targets to narrow down 
potential candidates, and their expression will be further evaluated using RT-
qPCR and western blotting.  Upon validation, the 3’UTR of theses candidates 
would then be cloned downstream of the luciferase reporter gene.  The TNBC 
cells would then be transfected with the plasmid containing the reporter gene as 
well as miR-4417 mimics to determine if the miRNA could bind to the 3’UTR 
and prevent the expression of the luciferase gene to infer the physical interaction 
between the miRNA and its target. 
 
2. Could the delivery of miR-4417 suppress malignant phenotypes of TNBC in vivo? 
While our preliminary results show that miR-4417 could suppress migration and 
tumorigenecity in vitro, it would be necessary to show if the effects could also be 
observed in mouse xenograft models.  This could be accomplished by injecting 
TNBC cells overexpressing miR-4417 into the mammnary fat pad of 
immunodeficient mice and determine the growth and spread of the tumors 




monitor their growth or injected intravenously to determine their ability to form 
metastatic colonies in the lungs of the mice.   
 
3. Could miR-4417 suppress malignancy in other cancer types? 
While our experiments show that miR-4417 could suppress TNBC progression, it 
would be interesting to explore its role in other cancer types/subtypes, where it is 
found to be lost or suppressed during progression.  The expression of miR-4417 
could be similarly evaluated in a panel of isogenic or non-isogenic EMT models 
to determine if it is suppressed in the mesenchymal state.  If so, it would be 
critical to perform functional assays and evaluate the effects of introducing miR-
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